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Abstract
Background: Non-fatal self-harm is one of the commonest reasons for adults’ emergency hospital attendance.
Although strongly associated with fatal and non-fatal repetition, there is weak evidence about effective interventions—
and no clear NICE guidance or clinical consensus concerning aftercare. We examined the practicability of a definitive
trial to evaluate problem-solving therapy (PST) to reduce repetition of self-harm; MIDSHIPS is a single-centre, parallel-
group, individually randomised controlled feasibility trial comparing treatment-as-usual (TAU) alone to TAU plus up to
six sessions of brief problem-solving therapy (PST) with adults who had recently attended hospital because of self-
harm. Objectives were to adapt the intervention for a UK setting, train therapists, recruit and randomise patients,
deliver PST under supervision, and establish comparative outcomes, assessed blindly.
Methods: We adapted the problem-solving intervention from an earlier trial and trained a mental-health nurse to
deliver it. Adult patients attending the general hospital for self-harm were recruited while undergoing psychosocial
assessment by the mental health team, and 62 were randomly allocated (32 TAU, 30 PST). The primary outcome
assessed repeat hospital attendance due to further self-harm 6months post-randomisation. Secondary outcomes
included participant-reported outcomes and service use at 3 and 6months post-randomisation.
Results: The recruitment period had to be extended and 710 patients screened in order to establish a trial sample of
the planned size (N = 62). A quarter of participants allocated to PST did not undertake the therapy offered; those who
received PST attended a median of three sessions. Secondary outcomes were established for 49 (79%) participants at 6
months; all participants’ hospital records were retrieved. Repetition of self-harm leading to hospital presentation
occurred in 19 of the 62 participants (30.6%, 95% CI 19.2%, 42.1%) within 6 months of randomisation. Promising
differential rates of self-harm were observed with an event rate of 23.3% (95% CI 8.2%, 38.5%) in the PST arm; and
37.5% (95% CI 20.7%, 54.3%) in TAU. Economic findings were also encouraging, with a small QALY gain (0.0203) in the
PST arm together with less reported use of the NHS in the PST arm (average £2120) than with TAU-only (£2878).
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Conclusions: The feasibility trial achieved its objectives despite considerable difficulties with recruitment—adapting
the PST, training a therapist, recruiting patients who had recently self-harmed, delivering the therapy, and establishing
primary and secondary outcomes. These data provide a robust platform for a definitive multicentre randomised
controlled trial of brief problem-solving therapy after hospital attendance due to self-harm.
Trial registration: Identification number and URL: ISRCTN54036115 http://www.isrctn.com/search?q=midships.
Registered: 13 January 2012
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Background
Non-fatal self-harm is one of the commonest reasons for
emergency hospital attendance in most countries and
places a high demand on mental and physical health ser-
vices; in the UK an estimated 150,000 people make over
220,000 hospital attendances each year [1]. Our defin-
ition of self-harm is the widely used one drawn from the
Multicentre Study of Self-Harm in England and used in
NICE guidance: intentional self-poisoning or self-injury,
irrespective of degree of suicidal intent [2].
Working age adults represent the majority of hospital
attendances due to self-harm [3, 4]. The excess of fe-
males is largely accounted for by young people in their
teens and twenties [4]. Over 70% of episodes leading to
hospital attendance are self-poisoning, with self-injury
(most often cutting) accounting for most of the rest—al-
though people who combine poisoning and injury in a
single episode form a smaller (less than 8%) subgroup
[5].
Over 15% of hospital-identified patients repeat within
1 year of an index episode [6, 7]. Repetition rates are
similar among males and females; higher in middle
adulthood than among younger or older patients [8];
and higher after self-injury than self-poisoning [5]. Most
repetition is non-fatal although suicide, occurring in just
under 1% of patients in the year following hospital dis-
charge after self-harm, is around 50 times more likely
than in the comparable general population [2, 7].
There is a poor evidence base about routine interventions
following hospital attendance [9]. The latest Cochrane re-
view found insufficient evidence to support case manage-
ment or remote contact procedures but some benefit from
psychotherapy comprising cognitive-behavioural therapy,
problem-solving therapy or both—with Cochrane-GRADE
evidence ratings only low-to-moderate [9]. NICE and UK
professional bodies recognise the shortage of evidence for
authoritative recommendations on treatment [10, 11]. As a
consequence, assessment and aftercare following self-harm
are highly inconsistent [12].
We therefore designed a large randomised controlled
trial (RCT)—the Multicentre Intervention Designed for
Self-Harm using Interpersonal Problem Solving (MIDSHI
PS)—among patients recruited from general hospitals,
using a brief cognitive-behavioural-based therapy—inter-
personal problem-solving therapy (PST)—comparing
outcome after PST plus treatment-as-usual (TAU) with
outcome following TAU alone. The therapy was de-
signed to be readily learned by mental health staff—such
as nurses, occupational therapists, and social workers—
and to be delivered in six sessions or fewer over 2
months. Although planning a multicentre RCT, we
began by developing and undertaking a feasibility trial in
one centre. The MIDSHIPS feasibility trial [13] aimed
to: (1) establish the intervention; (2) train therapists; (3)
recruit and randomise patients after hospital attendance
due to a self-harm episode; (4) deliver the therapy under
supervision; (5) monitor retention and adherence to PST
and characterise TAU; (6) collect follow-up data; and (7)
analyse the comparative outcomes between the two
groups, to inform the sample size of a definitive trial.
Methods
Setting
The feasibility trial took place in one Mental Health
Trust in Northern England that serves the cities of Leeds
and York. Leeds has a population of over 700,000 and is
one of UK’s largest city-regions; it has two large teaching
hospitals each with its own Emergency Department (ED)
service with overall management in a unified ED service.
The nearby city of York, population 200,000 with its
rural hinterland, has a single ED. In both cities, hospital
policy held that all patients who attended due to self-
harm should receive a psychosocial assessment by a clin-
ician who had suitable training, time, and supervision
for the task.
The problem-solving therapy
Problem-solving therapy (PST) is a long-established brief
and focused psychological intervention [14]. We (AH
and LP) adapted our PST manual and training
programme from ones used in self-harm trials in New
Zealand [15, 16]. The MIDSHIPS PST has seven steps
that are set out in detail in the PST training manual:
Step 1: Problem orientation
Step 2: Recognising and identifying problems
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Step 3: Selecting and defining a clear problem
Step 4: Generating solutions
Step 5: Decision making
Step 6: Creating and implementing a SMART* action
plan
Step 7: Reviewing progress
*Specific, measurable, achievable, relevant and time-
bound
Liaison psychiatry researcher, AH, and service-user
and activist in mental health, LP, also adapted the Client
Workbook used in the New Zealand trials. This work-
book takes the client through the problem-solving steps
and includes: summarising sections; checklists of com-
mon experiences raised in PST; lists created in the ses-
sions such as problems the client is currently
experiencing, with potential solutions; diagrams and
message boxes that illustrate and remind about the
problem-solving approach; and homework—activities to
practise between sessions. The workbook contains vari-
ous sheets: for problem-lists, brainstorming, solution
generation, and SMART (specific, measurable, achiev-
able, relevant to the problem, and time-bound) action
plans. For the present trial, the main additions were em-
phasis on planning for difficulty in implementing solu-
tions, and on barriers to attendance at sessions and risks
of dropping out of therapy.
Recruiting therapists
We recruited two therapists—a mental health nurse and
an occupational therapist. Their training in MIDSHIPS
PST was delivered over two consecutive days at the Uni-
versity of Leeds by two liaison psychiatrists (SH and
AH). Supervision was set up with a clinician-researcher
(AH), to be delivered approximately fortnightly.
Recruiting participants
Following meetings with senior clinicians in the ED and
in the self-harm team, we decided against using ED cli-
nicians to recruit participants. First, busy ED staff were
not likely to be sufficiently focussed on either mental-
health care or on recruitment to clinical trials. Second,
the Mental Health Trust providing the clinical assess-
ment of patients deemed it essential, for safety reasons,
for any recruited patients to be risk-assessed before tak-
ing part. Direct recruitment by ED clinicians would have
necessitated a separate, risk-assessing, clinical appoint-
ment for patients before the researcher would be
allowed to arrange to meet them.
Consequently, we used only mental health clinicians in
our two-stage recruitment procedure. At the routine psy-
chosocial assessment resulting from an episode of self-
harm, the mental health clinician (a mental health nurse
or psychiatrist) completed a screening schedule (one
double-sided sheet of paper) that established eligibility
and then briefly introduced the trial to the eligible patient,
passing on an A5-sized double-sided invitation card. Con-
sent was sought at this stage only to an approach from a
researcher who would later explain the trial more fully.
This consent, together with contact details, was recorded
on the invitation card—at the time of the clinical encoun-
ter or later: the invitation card could be folded and
gummed shut to become a postcard with a prepaid ad-
dress to the trial team. On receiving the card, from the cli-
nicians or mailed by the patient, the MIDSHIPS
researcher would contact the patient and arrange to meet,
where full written consent to random allocation in the
trial was sought following provision of the participant in-
formation sheet and a detailed discussion of what the re-
search entailed. We also placed our MIDSHIPS invitation
cards at a voluntary sector drop-in centre in Leeds to
which people who had self-harmed were sometimes di-
rected; in the event, none of the few expressions of inter-
est were from people who had, recently enough to fit
inclusion criteria, been to hospital as a consequence of
self-harm.
Inclusion and exclusion criteria
Inclusion criteria: aged 18 years or over, living in the
Mental Health Trust’s catchment area, and attendance
at the general hospital (at ED or as an in-patient) as a
consequence of self-harm in the previous 6 weeks.
Exclusion criteria: receiving from another research
project or clinical service an active intervention that
would conflict with MIDSHIPS therapy, insufficient
mental capacity to comply with trial requirements, insuf-
ficient proficiency in English to contribute to the data
collection needed for the research, known risk of vio-
lence, researcher unable to make contact and randomise
within 8 weeks of the most recent ‘index’ self-harm
episode.
Baseline data collection
The researcher arranged to meet potential participants
at a variety of clinical locations but, due to safety consid-
erations, not generally in their homes. The researcher
collected, on case report forms designed for the MIDS
HIPS trial, baseline information: basic personal informa-
tion, details of the index self-harm event and consequent
referral to hospital care, previous self-harm episodes,
current physical and mental health, social and medical
history, and current psychotropic medication. The re-
searcher also administered two questionnaires: the Short
Form 36 (SF-36) [17] health survey and a trial-specific
healthcare resource-use questionnaire.
Random allocation
Once consent and baseline data were collected, the re-
searcher arranged random allocation using a 24-h
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randomisation system provided by Leeds Clinical Trials
Research Unit. A computer-generated adaptive mini-
misation algorithm that incorporated a random element
was used on a 1:1 basis to allocate participants either to
PST plus TAU or to TAU alone. Minimisation was de-
signed to balance the treatment groups for four charac-
teristics: number of previous self-harm episodes leading
to hospital treatment prior to baseline assessment (one,
more than one); type of index episode (self-poisoning,
self-injury, both combined); gender (male, female); and
age (< 30, 30–59, 60 or over). Participants were told
their treatment allocation as soon as possible after ran-
domisation—by a researcher other than the one who
conducted the assessment and took consent—in order to
keep that researcher blind to allocation because of likely
later involvement in follow-up data collection. To ac-
complish this blinded arrangement, the Trials Unit made
two contacts: first, the problem-solving therapist was
told of the allocation to the treatment arm, and details
for making contact provided; second, a research assistant
who worked not with the project team but with the hos-
pital’s generic research support network (the nationally
funded Comprehensive Local Research Network)—who
was tasked with contacting each randomised patient, to
pass on their allocation.
Delivering the problem-solving therapy
Participants randomly allocated to the PST arm of the
trial were invited to attend on six occasions for 1-h ses-
sions with an additional ‘booster’ session, if wished-for,
approximately 6 to 8 weeks after the main sessions.
When appointments were not kept, the therapist made
reasonable attempts to reschedule. Sessions were
planned at 1- or 2-weekly intervals and were arranged at
mental health service premises or at participants’ homes,
according to patient preference and safety consider-
ations. Participants were discharged from the PST only
in the event of unscheduled failure to attend, or same-
day cancellation of, three consecutive appointments.
Ascertaining outcome and adherence data
Primary outcome
Repetition of self-harm leading to a hospital attendance
was the planned primary outcome in the definitive RCT.
Our participants gave permission for their attendance at
local hospitals to be tracked and recorded by the research
team at the end of the study. Researchers, blind to random
allocation, collected these ED attendances and admissions
by linkage of each participant to the electronic patient-
record system for Leeds general hospitals, and by a man-
ual search of the hospital’s record system for the York-
recruited participants—confirming by scrutiny of hospital
records in each case whether such attendances and admis-
sions were due to self-harm. Consequently, every
participant was accounted for with regard to the primary
outcome.
Other outcome data
At 3 and 6months post-randomisation, we collected by
postal questionnaire, followed up by telephone if there
was no response: self-reported episodes of self-harm, in-
cluding ones not leading to hospital attendance; the SF-
36 health survey; and a trial-specific schedule of health-
care resource used. TAU data were collected from the
Trust's records by another researcher. In routine prac-
tice, many patients attending the hospitals in the trial
because of self-harm are not offered aftercare, although
some are followed up in general psychiatric outpatient
clinics or referred to specialist services such as those
dealing with drug and alcohol use; return of patients to
the care of their general practitioner is the most usual
form of TAU.
With Ethics Committee agreement, we issued partici-
pants with £10 shopping vouchers on up to three occa-
sions: sent with the 3- and 6-month questionnaires, and
on a final occasion after a telephone interview by an un-
blinded researcher—who asked about therapy appoint-
ments, other treatments received outside of the trial, and
perceived burden and acceptability of the tasks con-
cerned with follow-up data collection.
Adherence to problem-solving therapy
Adherence of therapists and participants to the PST was
recorded in two ways: a record kept by therapists of ses-
sions undertaken or missed, and by the researcher’s re-
view of the therapy session notes for evidence of
adherence to the manual—as judged by completion of
workbook components such as problem lists, brain-
storming sheets, solution generation sheets, and SMART
action plans.
Analysis
Sample size
As a feasibility trial, the current study was not powered
to evaluate effectiveness [13]. We planned to recruit 60
participants over 6 months, randomised equally between
TAU and PST + TAU, to allow for the investigation of
parameters and outcomes for a definitive RCT.
Statistical analysis
As this was a feasibility study, formal hypothesis testing
was not conducted, and descriptive analyses were per-
formed on an intention-to-treat basis to provide esti-
mates of key parameters for the definitive RCT.
Summary statistics are reported for screening and re-
cruitment, therapeutic delivery and adherence, charac-
teristics of TAU, retention in treatment, and follow-up
rates for outcome—collected from hospital records and
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self-reported. To inform the sample size calculation for
the definitive trial, the occurrence and timing of repeat
self-harm leading to hospital attendance are summarised
according to trial arm at 6 months post-randomisation
(with 95% confidence intervals).
Health economics analysis
Data completeness of the SF-36 and the health service
resource-use questionnaire were examined by the health
economists (ST and JO’D), to inform the methods and
cost perspective to be used for a definitive trial. Indica-
tive costs for both arms were calculated through direct
observation of the treatment provided as part of the trial,
and through participant-reported resource use. Unit
costs for resources were obtained from the British Na-
tional Formulary, PSSRU unit costs of Health and Social
Care 2013 [18], and the Department of Health’s National
Schedule of Reference Costs [19]. Utilities were gener-
ated from the SF-6D preference-based measure based on
the participants’ responses to the SF-36 questionnaire at
each time point [20]. Utilities were then converted to
QALYs, multiplying utilities by the time spent in each
state, with quality of life linearly interpolated for the pe-
riods between the three observations provided in the
feasibility study (baseline, 3 and 6months).
Ethical and governance considerations
Ethical approval for the feasibility trial was granted by
the Leeds West Research Ethics Committee (Reference
12/YH/022); research governance approval was from the
UK National Institute for Health Research’s (NIHR) Co-
ordinated System for gaining NHS Permissions (CSP
88012); and health service permission to undertake the
research was granted by the local mental-health and
acute teaching-hospital Trusts’ research and develop-
ment departments. We set up a Trial Management
Group that met regularly to run the trial and an inde-
pendent Trial Steering Committee to provide independ-
ent and scientific oversight of the research [13].
Results
During an extended 13-month recruitment period, from
October 2012 to October 2013, 710 patients were
screened, of whom 392 (55%) were deemed eligible, and
62 (16% of eligible) were recruited. Almost half (48%) of
the ineligibility was because clinical staff thought the pa-
tient was a risk of violence—to therapy or research staff.
Other common reasons for clinical staff to exclude pa-
tients at this early stage were: lack of certainty about
whether there had been recent self-harm as defined
(23%), with alcohol and drug misuse sometimes raising
uncertainties; concurrent involvement in other research
or with a clinical service that would exclude their re-
cruitment (14%); and not living in the catchment area
(10%). Of the patients screened as eligible, 24% (94/392)
did not have the trial introduced to them. Although
some of these patients (34/94) were deemed too dis-
tressed or unwell, or were about to move from the
catchment area, or had other understandable reasons for
not being approached, it was not clear why the other 60
were not approached by clinicians; the research team
scrutinised these patients’ records soon after these atten-
dances and sent letters inviting response to 55 of these
60 people; no-one replied.
Recruitment and baseline
Recruitment to the trial is set out in Fig. 1. The rate of
screening by clinicians was markedly lower than we had
predicted (around 60 rather than 190 per month) and
the proportion of those eligible who were recruited (62/
392) was also below our forecast (16% rather than 20%).
We had correctly anticipated many barriers to recruit-
ment, and we made repeated attempts to set up success-
ful baseline interviews. In all, research staff made 1359
attempts at contacting the 175 patients consenting to re-
searcher contact regarding their inclusion in the trial.
With recruitment to the trial well below its proposed
trajectory, we extended the trial’s recruitment phase
from 6 to 13months (Fig. 2), and we extended our initial
recruitment catchment of Leeds to include the neigh-
bouring city of York—which was part of the same men-
tal health service Trust.
The trial recruited 62 participants who were randomly
allocated, 32 to TAU and 30 to TAU plus PST (Fig. 1).
Eight of the 62 participants were recruited from York,
allocated equally to trial arms. Just 6 baseline interviews
were at patients’ homes, with the rest at health-service
premises, mainly hospitals. Age and gender profiles were
reasonably similar among screened patients, eligible pa-
tients, those approached, and those enrolled. Trial par-
ticipants were a little older, were more often female, and
included more patients who had self-injured rather than
self-poisoned: screened mean (median) age was 34.1
(32.0) years compared with 35.2 (34.7) in the trial; the
proportion of females was 58% among those screened
and 65% in the trial; and in those screened, the propor-
tion who self-poisoned, self-injured, or combined both
methods were respectively 77%, 15%, and 8%, with the
corresponding proportions in the trial 65%, 19%, and
16%.
Characteristics of the sample
Baseline socio-demographic and clinical characteristics
(Table 1) were similar across the two trial arms. The
trial sample had a higher than expected proportion who
had combined self-injury with self-poisoning but other-
wise the proportions of poisoning and injury were
broadly similar to hospital observational data. There
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were high incidences of previous self-harm (79%) and of
treatment for mental health problems (84%). Alcohol
and substance use were typical of self-harm patient
populations.
Trial delivery and adherence
In no case did the research team in advance deem there
to be a safety concern over the conduct of an interview.
In two cases, the researcher had concerns, at the inter-
view, about the participant’s own safety and followed the
established risk protocol, without needing to trigger a
contact with health service agencies. No incidents arose
following baseline interviews.
Therapeutic delivery
Two therapists were successfully trained in the PST inter-
vention but one left early in the treatment phase after de-
livering therapy, under supervision, to one participant. All
PST (excluding 3 sessions for that one participant) was de-
livered by the remaining therapist. Supervision was regu-
lar, with the therapist receiving 25 face-to-face supervision
sessions, approximately two-weekly, each lasting on aver-
age 54min. During supervision, each new participant was
Fig. 1 Flow of potential and actual participants through the study
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discussed in detail, as were the other participants currently
in therapy.
Problem-solving therapy
Of the 30 participants allocated to PST, 13/30 (43%)
attended all planned sessions, another 10 (33%) attended
at least one session, and 7 (23%) attended no sessions.
The 23 (77%) participants attending at least one session
attended a median of three, with median time from first
to last session of 59 days (range 0 to 154), median time
from randomisation to last session 84 days (26 to 197),
and median duration of treatment 5.2 h (0.8 to 7.9). All
attendees were supplied with a workbook, 14/23 (61%)
completed all 7 therapy steps, 17 (74%) completed 6
steps or more, and 19 (83%) completed 4 or more of the
steps. The independent review of adherence reported
evidence that all 23 participants had been given a work-
book; 22 (96%) had a problem list; 20 (87%) had defined
a problem; and 17 (74%) had a brainstorm of possible
solutions and a SMART action plan. Overall, 16 (70%)
participants had evidence of compliance to all five of
these items, 18 (78%) to at least four, and 20 (87%) to at
least three.
Receipt of treatment as usual
Data were collected from mental-health service records
for all 62 participants; some form of TAU was received by
38 (61%) of participants: 16 (53%) of PST-arm participants
and 22 (69%) of TAU-arm participants. There were 797
TAU contacts (Table 2): 66% face to face and 34% over
the telephone, 94% of them individual rather than group
sessions. The contacts varied widely—from short tele-
phone calls made to remind patients about impending ap-
pointments, to follow-up psychosocial assessments
resulting from the self-harm episode, and to participation
in forms of therapy such as group-art; a large majority of
the contacts were for administrative and follow-up assess-
ment rather than therapeutic reasons (Table 2).
Data collection
Every participant provided all required baseline data. The
trial had a high response rate for return of questionnaire
booklets: 86% (53/62) at 3 months and 79% (49/62) at 6
months, with similar follow-up rates observed across trial
arms (Fig. 1). Most of the responses (52/53 and 42/49)
were returned by post; the greater use of telephone calls at
6months was largely due to pressure on researchers to ad-
here to time-limits as the project approached its end.
Fig. 2 Monthly and cumulative recruitment to the feasibility trial
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Table 1 Socio-demographic and clinical characteristics of the patients in the two treatment arms
Problem-solving and treatment as usual (N = 30) Treatment as usual (N = 32) Total (N = 62)
Female 19 (63%) 21 (66%) 40 (65%)
Age
Mean (SD) 34.8 (13.9) 35.6 (14.0) 35.2 (13.8)
Median (range) 35 (18 to 62) 35.5 (19 to 65) 35 (18 to 65)
Age group
<30 years 13 (43%) 15 (47%) 28 (45%)
30 to 59 years 15 (50%) 16 (50%) 31 (50%)
≥ 60 years 2 (7%) 1 (3%) 3 (5%)
Type of index event
Self-poisoning 20 (67%) 20 (62%) 40 (65%)
Self-injury 6 (20%) 6 (19%) 12 (19%)
Combined 4 (13%) 6 (19%) 10 (16%)
Self-harm before index event
No previous episodes 7 (23%) 7 (22%) 14 (23%)
One or more episode 23 (77%) 25 (78%) 48 (77%)
Previous treatment for mental health problem 25 (83%) 27 (84%) 52 (84%)
Living alone 10 (33%) 9 (28%) 19 (31%)
Alcohol consumption
Never 2 (7%) 3 (9%) 5 (8%)
Once a week or less 17 (56%) 14 (44%) 31 (50%)
Twice a week or more 11 (37%) 15 (47%) 26 (42%)
Substance use
Never 13 (43%) 12 (38%) 25 (40%)
Values are numbers (%) unless specified
Table 2 Treatment as usual accessed and received during follow-up
Problem-solving and treatment as usual (N = 30) Treatment as usual (N = 32)
Contacts and visits to facilities
Community Mental Health Team contacts 235 470
Emergency Department 8 13
Psychiatry clinic 10 19
Clinical Psychology clinic 0 27
Substance use unit 5 3
Other 1 6
Total 259 538
Nature of contacts or visits
Administration and follow-up, not therapy 226 527
Cognitive behavioural therapy 1 0
Dialectical behavioural therapy 1 1
Counselling 1 0
Group therapy 21 6
Other 9 4
Total 259 538
Values are numbers of episodes
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Questions on the forms were answered adequately: only 9
of the 94 forms had missing items—usually only one with
a maximum of three items missing. Hospital attendance
data were available for all participants.
Statistical outcomes
Further hospital attendances due to repeat self-harm
were our candidate for primary outcome in a multicen-
tre trial: the findings here are set out in Table 3. Repeti-
tion of self-harm leading to hospital presentation within
6 months of randomisation occurred in 19 of the 62 par-
ticipants (30.6%, 95% CI 19.2%, 42.1%). We observed
promising differential rates of self-harm: 23.3% (7/30,
95% CI 8.2 to 38.5%) of participants repeated 18 times in
the PST arm; and 37.5% (12/32, 95% CI 20.7 to 54.3%)
repeated 44 times in the TAU-only arm. The time to
repetition, however, showed a more complex pattern,
with speedier initial repetition among participants ran-
domised to problem-solving therapy (Table 3, Fig. 3).
The overall proportion repeating among those who had
no previous history of self-harm was considerably lower
(2/13, 15%) than in those with a history of earlier self-
harm (17/49, 35%).
Self-report of further self-harm was available for 54
(87%) participants who responded to at least one follow-
up questionnaire. Further self-harm was reported in the
6 months following randomisation for 32% (8/25) of par-
ticipants allocated to PST and 59% (17/29) of partici-
pants allocated to TAU. However 4/25 responses in the
PST arm were incomplete, covering either months 1–3
or 4–6 post-randomisation.
As almost all PST sessions were delivered by one ther-
apist, it was not possible to investigate the therapist clus-
tering effect.
Safety
No related unexpected serious adverse events (RU-SAEs)
were reported. One death (a TAU participant) was re-
ported after the 6-month follow-up period. A reassuring
trend of fewer SAEs, defined as hospital attendances,
was observed in the PST group with 26 attendances in
12 (40%) PST participants and 89 attendances in 20
(63%) TAU-only participants. Differential rates of hos-
pital attendance were corroborated by self-reported
health-resource use data at 3 months, with PST-arm par-
ticipants reporting fewer ED visits than TAU-only par-
ticipants (13% vs 58%). Similar self-reported hospital
attendance rates were reported at 6 months for the pre-
ceding 3-month period (30% vs 27%).
Health economics
Complete data for the health economics analysis were
available for a sample of 48 (77%) participants (22 in the
problem-solving arm, 26 in the treatment-as-usual arm);
there were also some participants who responded at one of
the two time periods. We generated the SF-6D preference-
based measure from the SF-36 and found a higher (better)
score for participants in the PST + TAU arm at all time
points, including baseline (see Table 4) although differences
between the two arms were never significant. When trans-
forming the SF-6D to QALYs, we found a gain of 0.0203
between the arms over the 6month follow-up—equivalent
to one additional week of perfect health for those receiving
problem-solving therapy over a year.
The average total reported service use (NHS) was esti-
mated at £1501 (SD 1440) at 3 months and £2120 (SD
2116) at 6 months in the problem-solving arm compared
with £3238 (SD 3731) at 3 months and £2878 (SD 3721)
at 6 months for those receiving only TAU. Both arms
Table 3 Return to hospital due to repetition of self-harm within 6 months, according to trial arm
Problem-solving and treatment as usual (N =
30)
Treatment as usual (N =
32)
Total (N =
62)
Repeated and attended hospital 7 (23%) 12 (38%) 19 (31%)
In participants with an event: n = 7 n = 12 n = 19
Mean time in months (SD) to first repeat event 1.2 (1.27) 1.6 (1.14) 1.4 (1.17)
Median time in months (IQR) to first repeat event 0.7 (0.4 to 1.2) 1.3 (1.0 to 2.1) 1.1 (0.6 to
1.9)
Mean number (SD) of events per participant 2.6 (1.40) 3.7 (2.74) 3.3 (2.35)
Number of repeat events 18 44 62
Type of repeat event
Self-poisoning 12 (67%) 36 (82%) 48 (77%)
Self-injury 3 (17%) 3 (7%) 6 (10%)
Combined 1 (6%) 2 (5%) 3 (6%)
Detail missing 2 (11%) 3 (7%) 5 (8%)
Mean number (SD) of events per participant (all 62
participants)
0.6 (1.28) 1.4 (2.43) 1.0 (1.98)
Values are numbers (%) unless specified
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received TAU with costs estimated at £1790 (SD 1934)
in the PST arm versus £2800 (SD 4094) in the TAU
arm. We estimated the cost of delivering PST assuming
that participants received six 1-h weekly sessions and
were offered an optional ‘booster’ session. We also esti-
mated the actual cost of receiving PST, including the
trial data on session attendance and duration of the ses-
sion, booster session attendance, and any other contacts
by the participant with the therapist (phone calls, dur-
ation of phone calls, face-to-face meetings, and text mes-
sages). The expected cost of the therapy was £343 if the
participant took up the optional booster session (versus
£184 in the observed trial data) and £294 (versus £171)
without a booster session.
Discussion
Objectives of the feasibility trial were met. The problem-
solving intervention was adapted from its earlier New
Zealand version, and we deemed it a practicable inter-
vention for hospital patients who had self-harmed in
England. We successfully recruited and trained two part-
time therapists from mental health staff in Leeds—al-
though our feasibility trial, in the event, depended on
just one of those therapists.
Fig. 3 Kaplan-Meier plot of time to self-harm event; vertical bars are 95% confidence intervals
Table 4 SF-6D according to treatment arm; values are SF-6D scores—the preference-based measure derived from the SF-36 health
survey
Treatment arm Timepoint Observations Mean Std Dev. Min. per patient Max. per patient
PST + TAU Baseline 22 0.5877 0.1066 0.3830 0.8280
3 months 22 0.6237 0.0907 0.4310 0.8410
6 months 22 0.6411 0.1104 0.3700 0.8520
TAU Baseline 26 0.5520 0.8695 0.3160 0.6790
3 months 26 0.5731 0.0952 0.4130 0.8100
6 months 26 0.5779 0.1164 0.3890 0.8870
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Recruitment
Recruitment to the trial proved a challenge and fell be-
hind schedule. Our planning estimates for identification,
introduction, and recruitment were mixed in their ac-
curacy. We only modestly overestimated that 20% of
those who were eligible would give their consent; in fact
it was 16%. On the other hand, only around one-third of
the expected number of patients (around 60 rather than
190 each month) was screened.
The main reason for failure to screen was a local or-
ganisational one. Although good personal relations with
the clinicians were maintained, our research was the vic-
tim of unfortunate timing. On the week when screening
and recruitment began, an unanticipated restructure of
the clinical teams was announced—with the self-harm
team to be amalgamated with a generic acute-care ‘Cri-
sis’ team. The actual changes in practice were enacted
after a 3-month period: the consequences were that,
throughout the trial, the screening and recruitment was
undertaken by an unsettled and clinically disparate team
of health-service professionals, many of whom were not
experienced in self-harm work. We were thereby unable
to count on as much commitment to the trial and its
procedures as we had expected from the developmental
work undertaken with the much-smaller, designated
self-harm team.
For 48% of the patients screened and found to be ineli-
gible for the trial, the reason was categorised as ‘known
risk of violence’. In the health service, a modest propor-
tion of patients would be ruled out of individual therapy
because of a clear propensity for violence, but clinicians
in the study were using a low threshold for such con-
cerns. We sought repeatedly to emphasise to clinical
staff that we were intending to mimic the non-trial
provision of PST should it become available as a routine
service, and people who were known to have taken part
in a past and non-severe violent episode would not ne-
cessarily be excluded from the therapy and therefore
ought not to be excluded from the trial.
We know that 60 patients were formally screened
by clinical staff and deemed eligible to take part but
did not have the trial introduced to them for unre-
corded reasons. NHS-employed staff examined the ED
records of these patients soon after they were dis-
charged from the hospital and sent letters introducing
the trial to 55 of them. Not one response was re-
ceived and we concluded that there was little chance
of recruitment if the research was not broached as
part of the clinical care of the current episode. Simi-
larly, many patients took away the addressed, pre-paid
study card but few were returned; nearly all our ini-
tial recruitment was confirmed by patients at the
point of contact with the clinician who had intro-
duced the idea of taking part in the trial.
We had expected that some patients, although they
had agreed to learn more about the trial through meet-
ing with the researcher, would fail to respond to our
email or telephone invitations. What we had not ex-
pected was so often to find that the contact details sup-
plied by the patients contained errors. Having written
consent to researcher-contact meant that we were some-
times able to correct these errors from hospital records
but there remained many occasions where we were un-
able to make the contact. We would, in future, pay more
attention to the method of collection of contact details—
possibly to include details, where appropriate and ac-
ceptable, of a relative or other significant person—
should a contact problem arise.
In more than a quarter of the cases where the re-
searcher and patient arranged to meet to discuss partici-
pation in the trial (23/85), the meeting never took place.
On more than half of these occasions, and without ex-
planation, the patient failed to attend, or to be at home,
or to open the door—and a further appointment did not
prove possible.
Trial participants and the two study arms
In clinical practice, greater uptake of talking therapies by
women than by men is an established finding [21] so we
had expected the modest excess of females in the trial
compared with the proportion of females among the pa-
tients screened. We recruited a higher-than-expected
proportion of patients who had self-harmed by combin-
ing self-injury with self-poisoning. If people who have
used combined methods of self-harm are preferentially
recruited, there are reasons to regard it as a good thing:
these patients have less favourable outcomes than those
who have only self-poisoned or only self-injured [5].
Data collection
We achieved complete recording of baseline data from
trial participants. When a trial’s participants are people
who have self-harmed, where levels of clinical engage-
ment and cooperation are uncertain, fears of poor ascer-
tainment of follow-up events are a realistic concern for a
research project. Here, researchers blind to the treat-
ment allocation were able to identify all ED attendances
for further episodes of self-harm over the follow-up 6
months by interrogating the record systems of the EDs
in Leeds and York. We explored the possibility of using
instead NHS Digital Hospital Episode Statistics for the
identification of these attendances, but the processes
were not sufficiently in place for us to gain permission
and access these data; we know from our recent clinical
trial of self-harm intervention in young people following
self-harm [22, 23] that it will be possible to use such a
procedure effectively in a future definitive trial similar to
MIDSHIPS.
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Non-return of follow-up questionnaires led to a re-
minder telephone contact from a researcher, who would
collect questionnaire data over the telephone should
postal return seem unlikely. The follow-up information
sought in writing from participants was kept strictly to
the minimum data deemed necessary for ascertainment
of the trial’s important outcomes, in order to minimise
the participants’ time and effort. As a result, rates of
completion and return of secondary outcome data were
high: 85% at 3 months and 79% at 6 months—higher
than in many trials and perhaps unexpectedly so among
a population of hospital patients who had self-harmed.
Delivery and adherence
Three-quarters (74%) of the participants who engaged in
the therapy completed six or seven of the seven
problem-solving steps—confirmed by the therapist’s ac-
count and corroborated by completed worksheets and
task-lists. Some of those who finished therapy before this
stage did so in negotiation with the therapist: the partici-
pant considered that he or she had made gains from
PST therapy and did not wish further attendance. That
leaves, however, around one in five participants who
began but did not persist with the therapy to a clinically
meaningful extent.
Outcomes
We found repetition rates for self-harm that were in the
direction of benefit for PST. Although we found sub-
stantial effect sizes, for proportions repeating and for
timing of repetition, precision was low as the study was
not powered to detect a difference between arms. The
follow-up data containing self-reports of further self-
harm events also suggested some promise from the PST.
Service-use and economic analysis
Our economic analysis suggested that PST was less
costly than TAU alone, with the difference mainly com-
ing from less self-reported service use and lower use of
TAU in patients allocated to PST. Intervention with PST
did point towards some benefits in quality-of-life mea-
sures but these findings were modest in effect size and
not statistically significant. We observed an inherent
problem in economic analysis when TAU is used in both
arms: it can be unclear whether self-reported resource
use is clearly distinct from data collected for TAU as
part of the trial, and there is a risk of double counting
some health care use.
CONSORT compliance
This written account of the MIDSHIPS trial complies
with the CONSORT statement’s extension to rando-
mised pilot and feasibility trials [24].
Conclusions
We found that it was feasible to produce a problem-
solving therapeutic intervention well suited to a wide
range of patients who had attended hospital after self-
harm. The therapy was readily and quickly taught, and
delivered without significant problems to people who
were willing to accept an offer of therapy. Recruitment
to the trial was slower than expected but we learned a
good deal about how to avoid or minimise, in a future
trial, a number of the impediments to the recruiting of
those who had recently self-harmed—and we substan-
tially improved recruitment in the second half of the
study period. In line with the difficulties described here,
we recruited a lower proportion of the eligible patients
than did comparable trials in self-harm. A group therapy
trial in Ireland of problem-solving skills training rando-
mised 38% of the eligible patients [25]. In New Zealand,
every eligible patient, in a trial using a care package that
included problem-solving therapy, was randomised—be-
cause the trial used a Zelen design in which randomisa-
tion preceded consent; 46% of those randomised then
gave their consent to their inclusion in the trial [16].
We successfully determined the primary outcome—re-
peat self-harm followed by hospital attendance—for all
participants without expending excessive researchers’
time. We understand that we would be able in future to
make such ascertainment more effective by using rou-
tinely collected data at a national level, using NHS Digital;
such a step would be less labour-intensive and would have
the advantage of identifying repeat episodes at hospitals
other than the ones in the recruitment centres. Secondary
outcome data and basic health economic measures
showed some shortfall in their ascertainment but, by keep-
ing the time and effort required for participants to a mini-
mum, we achieved completion rates that stand up well
against trials of complex interventions in general. The
comparison of repetition rates across the two arms of the
study, in favour of the problem-solving intervention, pro-
vides an encouraging preliminary finding.
Taken together, we believe that the experience and
findings of the MIDSHIPS feasibility trial provide a ro-
bust platform for a definitive multicentre randomised
controlled trial of brief problem-solving therapy, in the
recruitment setting of the psychosocial assessment that
should routinely result from hospital attendance due to
self-harm.
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